Application-level market taxonomy divides demand across emergency, supplemental oxygen, nebulisation, anaesthesia, and others, mapping clinical workflows to compressor duty cycles and profitability. Emergency installations require 100 % oil-free, instantaneous start/stop reliability and represent the fastest-growing sub-segment (11 % CAGR) as hospitals hard-code redundant backup systems. Supplemental oxygen therapy—predominantly COPD home care—absorbs 38 % of global units; reimbursement caps push manufacturers toward modular, 8 kg designs that maximise portability while protecting margins. Nebulisation, paediatric-weighted, favours low-noise (<45 dB) diaphragm compressors and accounts for 21 % of revenues despite modest ASPs. Anaesthesia applications, strictly regulated under ISO 7396-1, demand ultra-clean air (<0.1 mg m⁻³ oil), sustaining a 30 % price premium and 6 % share of volumes. Collectively these sub-applications delineate a revenue pool where reimbursement policy, not technology, dictates share trajectories.